BWS Financial maintains a Buy rating and $20 price target on ISIS Pharmaceuticals, Inc. (Nasdaq: ISIS), saying the stock could ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE